About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
Takeda Pharmaceutical Co. et al. v. Impax Laboratories, Inc.
3:13-cv-02416; filed May 29, 2013 in the Northern District of California
• Plaintiffs: Takeda Pharmaceutical Co., Ltd.; Takeda Pharmaceuticals U.S.A., Inc.; Takeda Pharmaceuticals America, Inc.
• Defendant: Impax Laboratories, Inc.
Takeda Pharmaceutical Co. et al. v. Sandoz Inc.
3:13-cv-02418; filed May 29, 2013 in the Northern District of California
• Plaintiffs: Takeda Pharmaceutical Co., Ltd.; Takeda Pharmaceuticals U.S.A., Inc.; Takeda Pharmaceuticals America, Inc.
• Defendant: Sandoz Inc.
Takeda Pharmaceutical Co. et al. v. TWi Pharmaceuticals, Inc.
3:13-cv-02420; filed May 29, 2013 in the Northern District of California
• Plaintiffs: Takeda Pharmaceutical Co., Ltd.; Takeda Pharmaceuticals U.S.A., Inc.; Takeda Pharmaceuticals America, Inc.
• Defendant: TWi Pharmaceuticals, Inc.
The complaints in these cases are substantially identical. Infringement of U.S. Patent No. 8,173,158 ("Methods of Treating Gastrointestinal Disorders Independent of the Intake of Food," issued May 8, 2012) following a Paragraph IV certification as part of defendants' filing of an ANDA to manufacture a generic version of Takeda's Dexilant® (dexlansoprazole, used for the treatment of all grades of erosive esophagitis, maintaining healing of esophagitis, and treating heartburn associated with symptomatic non-erosive gastroesophageal reflux disease). View the Impax complaint here.
Eli Lilly and Company et al. v. Perrigo Co. et al.
1:13-cv-00851; filed May 24, 2013 in the Southern District of Indiana
• Plaintiffs: Eli Lilly and Company; Eli Lilly Export S.A.; Acrux DDS Pty Ltd.
• Defendants: Perrigo Co.; Perrigo Israel Pharmaceuticals Ltd.
Infringement of U.S. Patent Nos. 8,435,944 ("Method and Composition for Transdermal Drug Delivery," issued May 7, 2013), 8,419,307 ("Spreading Implement," issued April 16, 2013), and 8,177,449 (same title, issued May 15, 2012) following a Paragraph IV certification as part of Perrigo's filing of an ANDA to manufacture a generic version of Eli Lilly's Axiron® (testosterone metered transdermal solution, used to treat males for conditions associated with a deficiency or absence of endogenous testosterone). View the complaint here.